Association of delayed adjuvant chemotherapy with survival after lung cancer surgery

JAMA Oncology

Volumn 3, Issue 5, 2017, Pages 610-619

  Salazar, Michelle C ^a   Rosen, Joshua E ^a   Wang, Zuoheng ^b   Arnold, Brian N ^a   Thomas, Daniel C ^a   Herbst, Roy S ^c   Kim, Anthony W ^a   Detterbeck, Frank C ^a   Blasberg, Justin D ^a   Boffa, Daniel J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION; EPIDEMIOLOGY; FEMALE; HUMAN; LUNG NEOPLASMS; LUNG RESECTION; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; POSTOPERATIVE PERIOD; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PNEUMONECTOMY; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 85020059755     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.5829     Document Type: Article

References (41)

1. Mohammed N, Kestin LL, Grills IS, et al. Rapid Disease Progression With Delay in Treatment of Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2011;79(2):466-472.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
3. Fedor D, Johnson WR, Singhal S. Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes. Surg Oncol. 2013;22(3):156-161.
4. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351-360.
5. Winton T, Livingston R, Johnson D, et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589-2597.
6. Douillard J-Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719-727.
7. Pignon J-P, Tribodet H, Scagliotti GV, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-3559.
8. Arriagada R, Auperin A, Burdett S, et al; NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267-1277.
9. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122(3):1037-1057.
10. Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, Decamp MM. Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer. Cancer. 2009;115(5):1059-1069.
11. Wu C-F, Fu J-Y, Yeh C-J, et al. Recurrence risk factors analysis for stage I non-small cell lung cancer. Medicine (Baltimore). 2015;94(32):e1337.
12. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e278S-e313S.
13. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e314S-e340S.
14. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 3.2016). 2015; https://www.nccn.org/professionals/physician-gls/f-guidelines-nojava.asp. Accessed December 8, 2015.
15. Kozower BD, Sheng S, O'Brien SM, et al. STS database risk models: predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg. 2010;90(3):875-881.
16. Teh E, Abah U, Church D, et al. What is the extent of the advantage of video-assisted thoracoscopic surgical resection over thoracotomy in terms of delivery of adjuvant chemotherapy following non-small-cell lung cancer resection? Interact Cardiovasc Thorac Surg. 2014;19(4):656-660.
17. Jiang G, Yang F, Li X, et al. Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer. World J Surg Oncol. 2011;9(1):170.
18. Nachiappan S, Askari A, Mamidanna R, et al. The impact of adjuvant chemotherapy timing on overall survival following colorectal cancer resection. Eur J Surg Oncol. 2015;41(12):1636-1644. EJSO.
19. Sun Z, Adam MA, Kim J, et al. Determining the optimal timing for initiation of adjuvant chemotherapy after resection for stage II and III colon cancer. Dis Colon Rectum. 2016;59(2):87-93.
20. Des Guetz G, Nicolas P, Perret G-Y, Morere J-F, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? a meta-analysis. Eur J Cancer. 2010;46(6):1049-1055.
21. Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol. 2016;2(3):322-329.
22. Irie M, Nakanishi R, Yasuda M, Fujino Y, Hamada K, Hyodo M. Risk factors for short-term outcomes after thoracoscopic lobectomy for lung cancer. Eur Respir J. 2016;48(2):495-503.
23. Rodrigues F, Grafino M, Faria I, Pontes da Mata J, Papoila AL, Félix F. Surgical risk evaluation of lung cancer in COPD patients - a cohort observational study [in Portuguese]. Rev Port Pneumol. 2006;22(5):266-272.
24. Boffa DJ, Rosen JE, Mallin K, et al. Perks and quirks to using the National Cancer Database for outcomes research: a review. JAMA Oncol. in press.
25. Strauss GM, Herndon JE II, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043-5051.
26. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26(24):3913-3915.
27. American College of Surgeons. The National Cancer Database 2013 PUF Data Dictionary. 2015; http://ncdbpuf.facs.org/node/259. Accessed December 1, 2015.
28. Wright CD, Gaissert HA, Grab JD, O'Brien SM, Peterson ED, Allen MS. Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model. Ann Thorac Surg. 2008;85(6):1857-1865.
29. American College of Surgeons. NCDB Getting Started - A Users Guide; National Cancer Database - Data Dictionary 2015; http://ncdbpuf.facs.org/content/ncdb?q=node/274. Accessed 12/10/2015, 2015.
30. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551-561.
31. Molinari N, Daurès J-P, Durand J-F. Regression splines for threshold selection in survival data analysis. Stat Med. 2001;20(2):237-247.
32. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29(9):1037-1057.
33. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399-424.
34. Haukoos JS, Lewis RJ. THe propensity score. JAMA. 2015;314(15):1637-1638.
35. Parsons LS. Performing a 1:N Case-Control Match on Propensity Score. Presented at: Proceedings of the 29th Annual SAS Users Group International Conference; May 9-12, 2004; Montreal, Canada.
36. Scagliotti GV, Fossati R, Torri V, et al; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95(19):1453-1461.
37. Ramsden K, Laskin J, Ho C. Adjuvant chemotherapy in resected stage II non-small cell lung cancer: evaluating the impact of dose intensity and time to treatment. Clin Oncol (R Coll Radiol). 2015;27(7):394-400.
38. Shugarman LR, Mack K, Sorbero MES, et al. Race and sex differences in the receipt of timely and appropriate lung cancer treatment. Med Care. 2009;47(7):774-781.
39. Booth CM, Shepherd FA, Peng Y, et al. Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study. Cancer. 2013;119(6):1243-1250.
40. Zhu Y, Zhai X, Chen S, Wang Z. Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non-small cell lung cancer in a single center. Thorac Cancer. 2016;7(4):399-405.
41. Douillard J-Y, Tribodet H, Aubert D, et al; LACE Collaborative Group. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol. 2010;5(2):220-228.